Boehringer to settle blood thinner drug suits for $650m


German-based firm Boehringer-Ingelheim has committed $650 million (£390 million) to settle around 4000 US court cases relating to its anticoagulant stroke prevention drug Pradaxa (dabigatran).

The patients bringing the lawsuits claim that the drug caused serious, and even fatal, bleeding. However, the US Food and Drugs Administration has backed up Boehringer’s view on Pradaxa’s risk-benefit profile compared to Warfarin, the established standard treatment. A study of 134,000 US patients found that, although Pradaxa is associated with an increased risk of major gastrointestinal bleeding, it presents no greater risk of heart attacks, and is more effective at preventing clot-related strokes, bleeding in the brain and death.

Boehringer lawyer Andreas Neumann said in a statement that the company expects most of the plaintiffs to accept the settlement. He stated that the company was confident it should win the suits based on its evidence, but explained that ‘we have to consider that juries composed of lay people have to decide about very difficult scientific matters. This does not allow reliable predictions for the outcome of a huge number of individual trials. This settlement allows our company to avoid the distraction and uncertainty of protracted litigation.’


Related Content

Chemistry World podcast - June 2013

3 June 2013 Podcast | Monthly

news image

We discover 300 years of chemistry in Edinburgh with Eleanor Campbell, and explore the secrets of the main group elements

Business roundup

28 July 2011 Business

news image

Industry news, August 2011

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

First flexible graphene display paves the way for folding electronics

11 September 2014 News and Analysis

news image

Team behind the bendy e-reader display hope to have a full colour graphene-based smartphone style screen within a year

Most Commented

Does life play dice?

3 September 2014 The Crucible

news image

Philip Ball wonders whether life evolved to exploit quantum phenomena, or if it’s just in our nature

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow